浙江东亚药业股份有限公司关于不向下修正“东亚转债”转股价格的公告

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has decided not to lower the conversion price of its convertible bonds, despite meeting the conditions for such a revision due to stock price performance [2][10]. Group 1: Convertible Bond Issuance and Terms - The company issued 6,900,000 convertible bonds on July 6, 2023, with a total fundraising amount of RMB 69 million, at a face value of RMB 100 each and a term of 6 years [3]. - The initial conversion price was set at RMB 24.95 per share, currently adjusted to RMB 20.28 per share [5][6]. - The conversion period for the bonds is from January 12, 2024, to July 5, 2029 [6]. Group 2: Conditions for Price Adjustment - The company’s stock price has been below 90% of the current conversion price (RMB 18.25) for 15 out of the last 30 trading days, meeting the conditions for a potential downward adjustment of the conversion price [2][9]. - The board has the authority to propose a downward adjustment, which requires a two-thirds majority approval from shareholders at a general meeting [7]. Group 3: Decision on Price Adjustment - The board of directors held a meeting on April 25, 2025, and decided not to lower the conversion price, maintaining this decision for a period of 6 months [10]. - If the conditions for a downward adjustment are met again after this period, the board will reconvene to consider the adjustment [10].